1
项与 异体人骨髓间充质前体细胞(Mesoblast) 相关的临床试验A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor.
100 项与 异体人骨髓间充质前体细胞(Mesoblast) 相关的临床结果
100 项与 异体人骨髓间充质前体细胞(Mesoblast) 相关的转化医学
100 项与 异体人骨髓间充质前体细胞(Mesoblast) 相关的专利(医药)
100 项与 异体人骨髓间充质前体细胞(Mesoblast) 相关的药物交易